A prior study showed that over-expressing the lncARSR gene accelerated the formation of liver fat both in vivo and in culture, suggesting that lncARSR may play a role in NAFLD and serve as a potential new treatment target for the disease [136]. This evidence concerns the gene LNCARSR and metabolic dysfunction-associated steatotic liver disease.